ClinicalTrials.gg
CompletedNCT00635232Updated Sep 16, 2011Results posted

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

A Phase 2 interventional study of irbesartan and placebo in Hypertension, sponsored by Ligand Pharmaceuticals. Completed at 40 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-09-16.

Sponsored by Ligand Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
544th of 1,779
261 · median 100
Started
2008
with 89 others
Phase 2
170 of 2,031
21 open now
Registered
399th of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 544th largest by enrollment of the 1,779 interventional ones that give a count, is one of 90 that started in 2008, is one of 170 in phase 2, and was the 399th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given PS433540.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • High Blood Pressure
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females 18 - 70 years
  • Mean seated Systolic Blood Pressure (SBP) ≥ 140 mmHg and \< 180 mmHg and mean seated Diastolic Blood Pressure (DBP) > 90 and \< 109 mmHg at two consecutive qualifying visits (Visits 3/3.5 and Visit 4). The mean difference in DBP between the two consecutive qualifying visits must be ≤ 10 mmHg.
  • Women of (WOCBP) must use two reliable forms of if sexually active. Alternatively, female subjects must be (for at least 1 year).

Exclusion criteria

Exclusion Criteria:

  • Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular (includes subjects who are known to have coronary artery disease), renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including malabsorption), endocrine/metabolic, hematologic, neurologic and psychiatric diseases.
  • History of other than adequately treated basal cell or squamous cell skin cancer.
  • Subjects with a history of myocardial infarction or (NYHA) class II-IV heart failure.
  • Subjects with a history of cerebrovascular accident or .
  • Subjects with clinically significant cardiac conduction defects, including second or third degree Atrioventricular Block (AV block), left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication.
  • Subjects with hemodynamically significant valvular disease.
  • Subjects with history of type 1 diabetes mellitus and subjects with a history of type 2 diabetes mellitus using antihyperglycemic medication (oral medication, insulin, or exenatide) are excluded.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
261 participants (actual)

Study arms

  • Active comparator
    Irbesartan 300mg

    Irbesartan 300 mg once daily

    Drug: irbesartan

  • Placebo comparator
    Placebo

    Blinded Placebo Treatment

    Drug: placebo

  • Experimental
    PS433540 200mg

    PS433540 200mg once daily

    Drug: PS433540

  • Experimental
    PS433540 400mg

    PS433540 400mg once daily

    Drug: PS433540

  • Experimental
    PS433540 800mg

    PS433540 800mg once daily

    Drug: PS433540

Interventions

  • 300 mg (2 x 150 mg capsules) once daily for 12 weeks

    Also known as: Avapro

  • Drugplacebo

    placebo capsules once daily for 12 weeks

  • 200 mg (2 x 100 mg capsules) once daily for 12 weeks

  • 400 mg (4 x 100 mg capsules) once daily for 12 weeks

  • 800 mg (8 x 100 mg capsules) once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.

    Time frame: 12 weeks

  2. The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.

    Time frame: 12 weeks

07

Results

Posted Sep 13, 2011
Limitations and caveats
The 800mg dose level was discontinued from further enrollment per protocol amendment due to findings from another PS433540 trial that suggested clinical benefit beyond 500mg was expected to be limited.

Participant flow

Participant flow — Overall Study
MilestoneIrbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mg
Started5859585828
Completed4439554820
Not completed14203108

Outcome measures

PrimaryChange From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
Time frame:
12 weeks
Reported as:
Mean · mm Hg
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
mm HgIrbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mg
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.-10.7 ± 14.321.8 ± 14.16-13.2 ± 13.61-14.2 ± 11.90-23.4 ± 18.70
SecondaryChange From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
Time frame:
12 weeks
Reported as:
Mean · mm Hg
Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.
mm HgIrbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mg
Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.-7.1 ± 9.190.2 ± 9.68-7.2 ± 8.34-9.2 ± 9.10-14.3 ± 10.53
SecondaryThe Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.
Time frame:
12 weeks
Reported as:
Number · participants
The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.
participantsIrbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mg
The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.175212816

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Irbesartan 300mg—0/58 (0%)19/58 (32.8%)
Placebo—0/59 (0%)20/59 (33.9%)
PS433540 200mg—0/58 (0%)10/58 (17.2%)
PS433540 400mg—1/58 (1.7%)25/58 (43.1%)
PS433540 800mg—0/28 (0%)17/28 (60.7%)
Most frequent serious events
Most frequent serious events
EventIrbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mg
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/580/590/581/580/28
Most frequent other events
Showing 10 of 31
Most frequent other events
EventIrbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mg
HeadacheNervous system disorders4/5810/590/583/582/28
DizzinessNervous system disorders2/582/590/582/583/28
Oedema PeripheralGeneral disorders2/581/592/584/583/28
Abdominal PainGastrointestinal disorders0/581/591/580/582/28
DiarrhoeaGastrointestinal disorders1/580/591/581/582/28
NauseaGastrointestinal disorders1/580/590/581/582/28
FatigueGeneral disorders3/581/590/584/580/28
Injury, Poisoning and Procedural ComplicationsInjury, poisoning and procedural complications2/582/592/584/580/28
Eye DisordersEye disorders0/583/590/580/580/28
MigraineNervous system disorders2/583/590/582/580/28

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Irbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mgTotal
<=18 years000000
Between 18 and 65 years5352504828231
>=65 years57810030
Age Continuous
Age Continuous(years)Irbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mgTotal
Mean51.5 ± 8.9754.2 ± 8.1253.2 ± 10.5853.4 ± 10.7151.4 ± 9.9252.9 ± 9.66
Sex: Female, Male
Sex: Female, Male(Participants)Irbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mgTotal
Female2330272617123
Male3529313211138
Region of Enrollment
Region of Enrollment(participants)Irbesartan 300mgPlaceboPS433540 200mgPS433540 400mgPS433540 800mgTotal
United States5859585828261
08

Study locations

40 sites
  • Advanced Clinical Research 1000 Forrest Place Suite 2 Pell City
    Pell City, Alabama 35128, United States
  • Premiere Pharmaceutical Research, LLC
    Tempe, Arizona 85282, United States
  • Genova Clinical Research AZ
    Tucson, Arizona 85741, United States
  • Advanced Clinical Research Institute
    Anaheim, California 92801, United States
  • Associated Pharmaceutical Research Center
    Buena Park, California 90620, United States
  • Clinical Trials Research CA
    Lincoln, California 95648, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90806, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Superior Regional Research, LLC
    Sacramento, California 95825, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Westlake Medical Center
    Westlake Village, California 91361, United States
  • Univ. Clinical Research Deland, LLC.
    Deland, Florida 32720, United States
  • Allan Graff
    Ft. Lauderdale, Florida 33308, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • North County Medical
    Sebastian, Florida 32958, United States
  • Q Clinical Research
    Decatur, Georgia 30035, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Midwest Institute for Clinical Research
    Indianapolis, Indiana 46260, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Cary Medical Research
    Cary, North Carolina 27518, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Unifour Medical Research NC
    Hickory, North Carolina 28601, United States
  • Northstate Clinical Research
    Lenoir, North Carolina 28645, United States
  • Triangle Medical Research NC
    Raleigh, North Carolina 27609, United States
  • Crescent Medical Research
    Salisbury, North Carolina 28144, United States
  • New Hanover Medical Rersearch
    Wilmington, North Carolina 28401, United States
  • Peidmont Medical Research Associates
    Winston Salem, North Carolina 27103, United States
  • The Lindner Center
    Cincinnati, Ohio 45219, United States
  • Delaware Smith Clinic
    Delaware, Ohio 43015, United States
  • Smith Clinic
    Marion, Ohio 43302, United States
  • COR Clinical Research, L.L.C
    Oklahoma City, Oklahoma 73103, United States
  • Brandywine Clinical Research Center
    Downingtown, Pennsylvania 19335, United States
  • Hypertension & Nephrology Inc
    Providence, Rhode Island 02904, United States
  • Punzi Medical Center
    Carrollton, Texas 75006, United States
  • Innovative Clinical Trials
    San Antonio, Texas 78229, United States
  • IMED Research PA
    San Antonio, Texas 78258, United States
  • Hampton Roads Center for Clinical Research
    Norfolk, Virginia 23502, United States
  • Gemini Scientific LLC
    Madison, Wisconsin 53719, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2008
First posted
Mar 13, 2008
Start
Mar 2008
Primary completionActual
Nov 2008
CompletionActual
Dec 2008
Results first posted
Sep 13, 2011
Last update
Sep 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00635232
Responsible party
Sponsor
First posted
Mar 13, 2008
Start date
Mar 2008
Primary completion
Nov 2008
Completion
Dec 2008
Results posted
Sep 13, 2011
Last update
Sep 16, 2011

Study contacts

Rene Belder, MD
study director · Ligand Pharmaceuticals
Joel Neutel, MD
principal investigator · Orange County Research Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sparsentan

Start the discussion